Abvc Biopharma (ABVC) Finished Goods (2018 - 2019)
Abvc Biopharma's (ABVC) quarterly Finished Goods came in at $94727.0 in Q4 2019, down 5.97% on a YoY basis from $100736.0 in Q4 2018, and up 3.71% quarter-over-quarter from $91341.0 in Q3 2019.
Powered by 
Analysis
Abvc Biopharma (ABVC) Finished Goods (2018 - 2019) Analysis & Trends
Abvc Biopharma (ABVC) has reported Finished Goods for 2 consecutive years, with $94727.0 the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Finished Goods fell 5.97% year-over-year to $94727.0; the trailing twelve-month figure through Dec 2019 stood at $94727.0 (down 5.97% YoY), and the FY2019 full-year result was $94727.0, down 5.97% from the prior year.
- Finished Goods improved to $94727.0 in Q4 2019 per ABVC's latest filing, from $91341.0 in the prior quarter.
- Across five years, Finished Goods topped out at $100736.0 in Q4 2018 and bottomed at $91324.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 94,727.00 |
| Sep 30, 2019 | 91,341.00 |
| Jun 30, 2019 | 91,324.00 |
| Mar 31, 2019 | 91,891.00 |
| Dec 31, 2018 | 100,736.00 |